AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$BOLT

Quinn William P. purchased $2K of BOLT

Quinn William P. (President, CEO and CFO) purchased 637 shares of Bolt Biotherapeutics, Inc. (BOLT) at $3.88 on 2026-06-05.

Original reporting
SEC EDGAR · Quinn William P.
Published Sep 21, 2026, 10:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 10:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BOLT
Neutral
high confidence
Mentioned
$BOLT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLTNeutralLow
01

Why it matters

The purchase is modest and unlikely to affect market perception significantly.

02

Market read

Minor insider purchase with limited trading relevance.

03

What to watch

Potential upcoming clinical data or financing events not disclosed here.

Relevance 4/10Novelty 4/10Timing: filed 2026-09-21

Background

Form 4 filings are primary disclosures of insider trades, used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$BOLTNeutralHigh confidence
Context

SEC Form 4 shows CEO/president purchased 637 shares at $3.876 each, a $2.5K insider buy.

Expected impact

minimal impact, possible slight positive bias

Evidence & confidence

Purchase size is trivial relative to market cap; no immediate trading signal.

Market effects

Sector

None; insider activity does not affect biotech sector broadly.

Regional

None; limited to company level.

Global

None

Counterpoint

What could challenge this read

Even small insider buys can signal confidence; could be a subtle bullish cue.

Key entities

  • Company
    Bolt Biotherapeutics, Inc.

    Biotech firm developing therapeutic candidates.

  • Person
    Quinn William P.

    President, CEO and CFO of Bolt Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BOLT insider trading history →

Related articles

$BOLTHighAI 8/10

Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary de

SEC EDGAR 8-K
$BOLTHigh

Bolt Biotherapeutics, Inc. (BOLT): Completion of Acquisition or Disposition of Assets

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications • Transactions position the company to advance Prana’s pipeline of next-generation, half-lif

SEC EDGAR 8-K